eSense-Lab

ASX ANNOUNCEMENT

7 February 2019

eSense Signs Commercial Distribution Agreement to Supply E-Juice in USA and Canada

Highlights

- Signs a multi-year distribution agreement for the supply of e-Juice to VaporSpec Ltd
- Annual sales of up 5 million bottles in the third year of this agreement¹
- VaporSpec is a California-based company distributing products to the North American vaping industry

Life science company eSense-Lab Limited (ASX:ESE) ("eSense" or the "Company") is pleased to announce the continuation of its commercialisation activities via an agreement that will see its products distributed throughout North America.

The Company has finalised negotiations and signed a commercial non-exclusive distribution agreement for the supply of e-Juice to VaporSpec Inc.² ("VaporSpec"), a California based company distributing products to the vaping industry.

After successfully concluding three months of negotiations, VaporSpec will distribute several different e-Juice products that will be produced by eSense and shipped to VaporSpec for distribution in the USA and Canada.

The agreement calls for minimum quantities of e-Juice to be supplied in 10 ml. bottles. Minimum annual quantities rise from 450,000 bottles in the first year to 5 million bottles in year three of the agreement. The agreement automatically renews every three years. The quantities quoted are subject to a successful evaluation period with the purchase of at least 150,000 bottles during the first six months of the agreement.

VaporSpec is a premier distributor of products to both wholesale and retail vaping market. E-liquids are used for vaporising or "vaping" and are a safer alternative to smoking. The agreement with VaporSpec follows a similar agreement signed with a UK-based entity (ASX Announcement: 6 December 2018).

The agreement culminates a long successful negotiation and expands the opportunities for use of the Company's terpenes in a variety of industry sectors. eSense's continuing mission, the commercialisation of its terpenes, and penetration of the global e-liquid is showing success as evidenced by this new distribution agreement.

eSense's CEO Mr. Haim Cohen: "I am extremely pleased to announce to the market the distribution agreement eSense has signed with VaporSpec, a major player in the USA's West Coast vaping market. I am excited about this agreement and the various opportunities that the future holds for eSense. We are performing additional testing programs with companies in the other markets as well, including the development of different products that will allow the company to grow in the food additive, food supplements, e-cigarette and other related markets. I look forward to informing the market on the continuation of our activities and successes".

ENDS

¹ Subject to a successful 6 month evaluation period.

² <u>https://www.vaporspec.biz/</u>



For further information, please contact:

Company Secretary lan Pamensky +61 414 864 746 Media & Investor Enquiries
Julia Maguire
+61 419 815 386
julia@thecapitalnetwork.com.au

Corporate Advisor
EverBlu Capital
+61 2 8249 0000
info@everblucapital.com

About eSense-Lab | Registered Office: Level 14, 330 Collins Street, Melbourne, Victoria, Australia, 3000

eSense-Lab Ltd (ASX:ESE) is a life sciences research and development company creating natural plant-based products that heal and delight. Headquartered in Israel, eSense-Lab combines genetics, mRNA, protein expression and phytochemical profiles to generate a comprehensive model of rare or high value plants.

With multi-disciplinary R&D expertise, unique reverse engineering capabilities and game-changing techniques that enable reengineering the chemical composition found in plants, e-Sense Lab re-formulates these for numerous commercial applications.

Cannabis is the first plant eSense is targeting for re-engineering. eSense is creating a cannabis plant that has all the characteristics of the real thing but does not contain the psychoactive and more heavily regulated cannabinoid compound.

To learn more about eSense-Lab, please visit www.esense-lab.com